Optiscan Imaging (ASX: OIL) Launches Second Cancer Trial: Why This MedTech Stock Looks Like a Buy

Optiscan Imaging (ASX: OIL) has partnered with Australian Clinical Labs to launch Australia’s first-in-human head and neck cancer imaging study. The ground-breaking study will recruit 50 patients at the St John of God Healthcare campus in Murdoch and will be led by prominent Perth head and neck cancer surgeon Dr Chady Sader. For investors tracking this emerging MedTech name, the announcement marks an important step in building the clinical evidence base needed for US FDA approval and suggests management is executing well on its commercialisation roadmap.

What are the Best ASX Healthcare stocks to invest in right now?

Check our buy/sell tips

Optiscan Builds Clinical Momentum with Second Active Cancer Study

Optiscan has taken a major step forward by running two clinical trials at the same time. Alongside its 50‑patient breast cancer study in Melbourne, the company has now launched a Perth‑based program focused on head and neck cancers. Both trials use Optiscan’s full product suite, including the InVue surgical imaging device and InForm digital pathology platform, giving the technology a broad test in real clinical settings.

In practical terms, InVue is a pen‑sized digital microscope that lets surgeons see cancer cells in real time during operations. This means doctors don’t have to wait days for lab results, potentially speeding up treatment decisions and improving patient outcomes.

The head and neck cancer market represents a major opportunity, with more than 72,000 expected US cases in 2025 and HPV‑related cancers on the rise. Optiscan’s non‑interventional study design means vital imaging data can be collected quickly without disrupting patient care, helping build evidence for wider adoption. Together, these trials highlight Optiscan’s growing clinical footprint and the potential of its technology to reshape cancer surgery.

Why This Matters for Optiscan’s FDA Approval Push

This new study is more than just another trial; it’s a key step towards US approval. The data collected will help Optiscan prepare its submission to the Food and Drug Administration (FDA) and strengthen its AI imaging technology for oral cancer. By training its system on different cancer types, Optiscan is building a strong competitive edge.

The company plans to use the study results to file for FDA marketing approval in 2026. Its partnership with Australian Clinical Labs adds credibility, giving access to a wide lab network for real-world testing. With multiple cancer studies underway, Optiscan reduces the risk of relying on just one application, making its path to success more secure.

The Investor’s Takeaway

Optiscan’s story is getting stronger. With two cancer studies now running, the company is building the evidence it needs for FDA approval. The share price has already jumped more than 150% in the past year, showing that investors are paying attention. Its partnership with Australian Clinical Labs adds credibility, and having multiple cancer programs reduces the risk of relying on just one. The company also has enough cash, boosted by a recent R&D refund, to keep funding its trials.

Still, this is a speculative play. Optiscan is not yet profitable, and none of its devices have regulatory approval. The FDA process is uncertain, and the current market value already assumes a lot of future success. For risk‑tolerant investors with a two-to-three-year view, Optiscan could be worth buying, but it may be wiser to build a position slowly. After such a big rally, waiting for a pullback could offer better entry points